Digital Media briefs

Share this article:
Takeda Pharma­ceuticals North America partnered with the American Association of Clinical Endocrinologists to launch the Diabetes Navigator (DiabetesNavigator.AACE.com), a compendium of type 2 diabetes information for patients and caregivers. The site—divided into disease management, lifestyle and tools sections—offers links to reputable sites on the disease, information on working with a health team and maintaining a healthy lifestyle, as well as facts, figures, tips and trackers on managing the disease.

Elsevier added 950 e-books to Research4Life, a public-private partnership aimed at achieving the UN's Millennium Development Goals by providing the developing world access to critical scientific research. The e-books build on 800 existing Elsevier science and technology books.

Mayo Clinic launched an app aimed at helping patients with contact dermatitis select safe skin care products that won't cause a flare-up. Sufferers often find that even those moisturizers, sunscreens or shampoos labeled “hypoallergenic” will trigger redness, skin lesions or swelling. The Contact Allergen Replacement Database gives them a shopping list of allergen free products.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?